|
|
|
| Clinical study of quetiapine combined with memantine in treatment of BPSD of Alzheimer's disease and its influence on the mental burden of caregivers |
| LIU Peng1, LI Zhiyong2, DUAN Feng3, WANG Qian4 |
1. Department of Geriatric Medicine, 3. Neurology Department, the Sixth Medical Center of Chinese PLA General Hospital, Beijing 100142,China;
2. Psychological Department, Beijing Chuiyangliu Hospital, Beijing 100021,China;
4. Emergency Department, the Third Medical Center of Chinese PLA General Hospital, Beijing 100039,China |
|
|
|
|
Abstract Objective To investigate the clinical effect of quetiapine combined with memantine in the treatment of behavioral and psychological symptoms of dementia (BPSD)of Alzheimer's disease and its influence on the mental burden of the caregivers. Methods Sixty male patients diagnosed as AD combined with BPSD who were treated in The Sixth Medical Center of Chinese PLA General Hospital from January 2020 to January 2021 as well as 60 caregivers were randomly divided into experimental group (n=30) and control group (n=30). The control group were treated with Memantine, while the experimental group were treated with memantine combined with quetiapine for 4 weeks. Before treatment and at the end of 4 weeks' treatment, evaluation of MoCA, BEHAVE-AD and their caregivers' SCL-90 scores was made. Results Before treatment of both groups, there was no significant difference (P>0.05) in MoCA, BEHAVE - AD and caregivers' SCL-90 score. MoCA scores in both groups after treatment were improved, and the difference was statistically significant (P<0.05). After treatment, the BEHAVE-AD score and caregiver SCL-90 score in the experimental group were improved, and the difference was statistically significant (P<0.05), while those scores in the control group were not improved and there was no statistical difference (P>0.05). Conclusions Quetiapine combined with memantine has a better therapeutic effect and it can also help relieve the mental burden of the patient's caregivers.
|
|
Received: 15 November 2021
|
|
|
|
|
|
| [1] |
Soria L J A, González H M, Léger G C. Alzheimer's disease[J]. Handb Clin Neurol,2019,167(5):231-255.
|
| [2] |
Eratne D, Loi S M, Farrand S, et al. Alzheimer's disease: clinical update on epidemiology, pathophysiology and diagnosis[J]. Australas Psychiatry,2018,26(4):347-357.
|
| [3] |
Ohno Y, Kunisawa N, Shimizu S. Antipsychotic treatment of behavioral and psychological symptoms of dementia (BPSD): management of extrapyramidal side effects[J].Front Pharmacol,2019,10(5):1045.
|
| [4] |
Yunusa I, Alsumali A, Garba A E, et al. Assessment of reported comparative effectiveness and safety of atypical antipsychotics in the treatment of behavioral and psychological symptoms of dementia: a network meta-analysis [J].JAMA Netw Open,2019,2(3):e190828.
|
| [5] |
Bessey L J, Walaszek A. Management of behavioral and psychological symptoms of dementia [J]. Curr Psychiatry Rep,2019, 21(8):66.
|
| [6] |
Liu Z, Heffernan C, Tan J. Caregiver burden: a concept analysis[J]. Int J Nurs Sci, 2020,7(4):438-445.
|
| [7] |
Bergvall N,Brinck P,Eek D, et al. Relative importance of patient disease indicators on informal care and caregiver burden in Alzheimer's disease [J].Int Psychogeriatr,2011,23(1):73-85.
|
| [8] |
Chakraborty S, Lennon J C, Malkaram S A ,et al. Serotonergic system, cognition, and BPSD in Alzheimer's disease[J]. Neurosci Lett,2019,704(6):36-44.
|
| [9] |
Preuss U W, Wong J W, Koller G.Treatment of behavioral and psychological symptoms of dementia: a systematic review[J]. Psychiatr Pol,2016,50(4):679-715.
|
| [10] |
Magierski R, Sobow T, Schwertner E, et al. Pharmacotherapy of behavioral and psychological symptoms of dementia: state of the art and future progress[J].Front Pharmacol,2020,11(2):1168.
|
| [11] |
Gauthier S, Loft H, Cummings J. Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis[J]. Int J Geriatr Psychiatry,2008,23(4):537-545.
|
| [12] |
Fox C, Crugel M, Maidment I, et al. Efficacy of memantine for agitation in Alzheimer's dementia: a randomised double-blind placebo controlled trial[J]. PLoS One, 2012,7(3):e35185.
|
| [13] |
Kales H C,Gitlin L N,Lyketsos C G.Assessment and management of behavioral and psychological symptoms of dementia [J].BMJ,2015,350(3):h369.
|
| [14] |
Schneider L S,Dagerman K,Insel P S.Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials[J]. Am J Geriatr Psychiatry,2006,14(3):191-210.
|
| [15] |
Tulek Z,Bayka D,Erturk S, et al. Caregiver burden, quality of life and related factors in family caregivers of dementia patients in Turkey [J]. Issues Ment Health Nurs,2020,41(8):741-749.
|
| [16] |
Liu S, Li C H, Shi Z H,et al.Caregiver burden and prevalence of depression, anxiety and sleep disturbances in Alzheimer's disease caregivers in China[J].J Clin Nurs, 2017,26(9):1291-1300.
|
| [17] |
Kieboom R V D,Snaphaan L,Mark R,et al. The trajectory of caregiver burden and risk factors in dementia progression: a systematic review[J]. J Alzheimers Dis,2020,77(3):1107-1115.
|
| [18] |
Lloyd J, Muers J, Patterson T G,et al. Self-compassion, coping strategies, and caregiver burden in caregivers of people with dementia[J].Clin Gerontol, 2019,2(1):47-59.
|
| [19] |
Yu H M, Wang X C, He R L,et al.Measuring the caregiver burden of caring for community-residing people with Alzheimer's disease[J]. PLoS One, 2015,10(7):e0132168.
|
| [20] |
Tsai C F, Hwang W S, Lee J J, et al. Predictors of caregiver burden in aged caregivers of demented older patients[J] .BMC Geriatr, 2021,21(1):59.
|
| [21] |
Alzheimer's Association.2016 Alzheimer's disease facts and figures[J].Alzheimers Dement,2016,12(4):459-509.
|
| [1] |
. [J]. Med. J. Chin. Peop. Armed Poli. Forc., 2021, 32(9): 817-820. |
|
|
|
|
2022, Vol. 33 
